Jeffrey Cooper,  MS, OD, FAAO

Jeffrey Cooper, MS, OD, FAAO

Jeffrey Cooper received his O.D from Pennsylvania College of Optometry in 1971 and an M.S. in Physiological Optics from State University of New York in 1978. He completed a residency in Binocular Vision and Visual Perception in 1971 and subsequently was appointed the co-chairman of the vision therapy department. He taught at the SUNY College of Optometry from 1971 to 2015, where he obtained the rank of Clinical Professor. He taught strabismus and amblyopia diagnosis in both the professional program and the residency program; in addition, he taught in the primary care department, vision therapy department and ocular disease departments. He retired as Professor Emeritus.

Dr. Cooper has authored over 60 peer reviewed papers dealing with anomalies of binocular vision, stereopsis, and glaucoma. He served as the principal investigator of two NIH/NEI clinical trials. He lectures in the greater NY basic science program for Ophthalmology each year at Columbia University. He was one of the first optometrists to incorporate atropine into his practice to slow the progression of myopia.

In addition, Dr. Cooper is the inventor of both Computer Orthoptics and the HTS programs which were used in the CITT clinical trials. He is on the advisory boards of VTI, Alcon, Treehouse, Computer Orthoptics, and Magic Leap.

1

Resource
Innovations in Binocular Vision Disorder Testing and Treatments: Interview with Denise Drace-Brownell, JD, MPH, and Jeffrey Cooper, MS, OD, FAAO
Optometry Industry Info
Innovations in Binocular Vision Disorder Testing and Treatments: Interview with Denise Drace-Brownell, JD, MPH, and Jeffrey Cooper, MS, OD, FAAO

The impact of BV disorder on individuals can be devastating—ranging from severe learning difficulties to decreased function leading to job loss to deficiency in everyday activities. However, education, broader testing, and innovations in treatment offer hope.

December 22, 2021